ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 8, 2021

8:30AM-10:30AM: Abstract Number: 1193

Musculoskeletal Ultrasound Instruction in US and Canadian Pediatric Rheumatology Fellowship Programs

Professional Education Poster (1170–1195)

8:30AM-10:30AM: Abstract Number: 1171

Needs Assessment of a Rheumatology Curriculum for Internal Medicine Residents

Professional Education Poster (1170–1195)

8:30AM-10:30AM: Abstract Number: 1002

Nerve and Airway-associated Tissue Resident Pulmonary Macrophages Limit Infiltration and Alter Phenotype of Infiltrating Monocytes and Fibrocytes to Reduce Pulmonary Fibrosis

Innate Immunity Poster (0992–1006)

8:30AM-10:30AM: Abstract Number: 1195

NLP-Based Clustering Methods Can Efficiently Categorize Scientific Abstracts for Medical Conferences

Professional Education Poster (1170–1195)

8:30AM-10:30AM: Abstract Number: 1362

No Change in Bone Marrow Edema of the Sacroiliac Joints and Spine After High Intensity Interval Training in PsA

Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)

8:30AM-10:30AM: Abstract Number: 1320

Obesity and Its Associations with Clinical Manifestations and Disease Burden of Patients with Spondyloarthritis: An Ancillary Study from the ASAS-perSpA Project

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)

8:30AM-10:30AM: Abstract Number: 1117

Ocular Scleral Pathology: Clinical Features and Systemic Treatment in 175 Patients from a Single University Center

Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)

8:30AM-10:30AM: Abstract Number: 1044

Older Patients with Rheumatic Disease Are Commonly Prescribed Potentially Inappropriate Medications

Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

8:30AM-10:30AM: Abstract Number: 1284

One Third of Lupus Nephritis Patients Classified as Complete Responders Continue to Accrue Progressive Renal Damage Despite Resolution of Proteinuria

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1065

Optimizing Joint Pain EConsult Referrals in an Underserved Region of Southern California

Health Services Research Poster II: Care Models and Innovation (1061–1082)

8:30AM-10:30AM: Abstract Number: 1021

Organic Dust Exposure Induces Post-translational Protein Modifications and a HLA-DR4-dependent Pro-inflammatory Lung Phenotype in a Murine Model of Interstitial Lung Disease

RA – Animal Models Poster (1014–1021)

8:30AM-10:30AM: Abstract Number: 1130

Osteoarthritis Patients Feel Their Tissue Remodeling

Osteoarthritis – Clinical Poster III (1118–1134)

8:30AM-10:30AM: Abstract Number: 1134

Osteoarthritis Risk Is Increased in Patients with Atopic Disease

Osteoarthritis – Clinical Poster III (1118–1134)

8:30AM-10:30AM: Abstract Number: 1017

Osteoclast-Specific Transmembrane Protein (OC-STAMP) Regulates Osteoclastogenesis and Inhibits Inflammation in an Acute Arthritis Model

RA – Animal Models Poster (1014–1021)

8:30AM-10:30AM: Abstract Number: 1135

Osteoporosis Assessment and Outcomes in Candidates for Liver Transplantation in a Tertiary Center

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster (1135–1149)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].